Already a Bloomberg.com user?
Sign in with the same account.
Sept. 28 (Bloomberg) -- Astellas Pharma Inc. will discontinue global development of darexaban maleate, a drug for preventing strokes and blood clots, because competition has increased in the sector and it can’t find a partner to develop and commercialize the drug.
The discontinuation won’t affect the Japanese drugmaker’s earnings forecast for this fiscal year, according to a statement on Astellas’ website today.
To contact the reporter on this story: Go Onomitsu in Tokyo at email@example.com
To contact the editor responsible for this story: Gearoid Reidy at firstname.lastname@example.org